OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc. (ticker: OKUR) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of OKUR's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. OKUR reported $0 in revenue and -$15.16M for the period ending 2024-12-31, with operating cash flow of -$12.94M. Cash and equivalents stood at $192.11M (up 98.7% year-over-year). Total assets of $198.69M exceed total liabilities of $14.34M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

OKUR Risk Flags

Consolidated view of every risk_flag row OKURhas surfaced across DredgeCap's extractor pipeline (auditor changes, late filings, delistings, going-concern, dilution, etc.). Each row carries a verbatim source_excerpt and links to the source SEC filing on EDGAR.

Category	Severity	Source	Excerpt	EDGAR
Auditor Change	low	10-K · Mar 10, 2025	PCAOB-tagged auditor in 10-K filed 2025-03-10 (accession 0000950170-25-036252) was 'KPMG LLP' (PCAOB Firm ID: 185). Prior 10-K/A filed 2024-04-26 (accession 0000950170-24-048631) was 'Ernst & Young LLP' (PCAOB Firm ID: 42).	view ↗

Related on OKUR

Auditor & opinion →

Source for auditor_change + going-concern flags.

Share-count dilution →

Source for dilution + convertible-debt flags.

Risk-flag rows are produced by DredgeCap's extractor pipeline (lib/extract-auditor-changes, extract-late-filings, etc.). Each row carries a verbatim source_excerpt from the underlying SEC filing — no AI-generated language. Refresh runs daily. Not financial advice.